Abstract
Background In vivo and observational studies suggest anti-hyperlipidaemic and -diabetic medications (fibrates and glitazones respectively) may have a role in primary prevention and progression of brain tumours by targeting PPAR-α and -γ, respectively.
Methods We conducted a case-control and clinical cohort study within the UK Clinical Practice Research Datalink. We identified adults (aged 18 years+) with primary or secondary brain tumours diagnosed between 2000-2016 prescribed either fibrates or glitazones and identified four controls based on age, sex and drug exposure duration. Multivariable logistic regression analysis estimated an association between drug exposure and brain tumour status. Cox’s survival models were used to look at risk of mortality.
Results 1,916 cases were prescribed a fibrate and 445 cases a glitazone. Our analyses showed little evidence of an association between fibrates and either risk or mortality of brain tumours (adjusted odds ratio for ever exposed PPAR-α 0.98, 95% CI: 0.77, 1.23; adjusted hazard ratio for ever exposed 0.91; 95% CI: 0.76, 1.09). We observed a reduced risk with a per-year increase in exposure duration for glitazones (adjusted odds ratio 0.88, 95% CI: 0.81, 0.96, P=0.002) but no major mortality benefit (adjusted hazard ratio 0.99, 95% CI: 0.80, 1.23).
Conclusions Our results suggest longer duration exposure to glitazones is associated with a reduced risk of primary and secondary brain tumours but no large effect on mortality. We failed to find any strong evidence of a protective effect on risk or mortality for fibrate exposure. Further studies are required for replication and to provide more precise effect estimates.
Key Points
Repurposing existing drugs that target PPAR-α and -γ receptors may have a role in prevention and progression of brain tumours.
We observed a reduced risk between duration of glitazones and both primary and secondary brain tumours but no major reduction on mortality
We observed no major reduction of risk or mortality with fibrates
Future studies need to be undertaken to ensure replication and obtain more precise estimates
Importance of Study The incidence of brain tumours appears to be increasing with a growing impact on years of life lost. Therapeutic options are limited, either for primary prevention or to prevent mortality of disease once developed. We investigated whether two commonly prescribed families of drugs (fibrates and glitazones) could offer potential drug-repurposing options in reducing brain tumour incidence or progression as informed by previous in vivo and observational studies. Our analyses suggest that glitazones are associated with a decreased brain tumour risk. These results can help guide future research into drug re-repurposing for brain tumour treatment.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
Funding Statement
The MRC/University of Bristol Integrative Epidemiology Unit (IEU) is supported by the MRC and the University of Bristol (MC_UU_12013/1, MC_UU_12013/2). JWR is supported by a joint studentship from NHS North Bristol Trust and Bristol Tumour Bank (SOCS/SJ1447). RMM is supported by a Cancer Research UK Programme Grant, the Integrative Cancer Epidemiology Programme (C18281/A19169). JWR and RMM are members of the MRC IEU which is supported by the Medical Research Council and the University of Bristol (MC_UU_12013/1-9). RMM is supported by the National Institute for Health Research (NIHR) Bristol Biomedical Research Centre which is funded by the National Institute for Health Research and is a partnership between University Hospitals Bristol NHS Trust and the University of Bristol. The views expressed in this publication are those of the author(s) and not necessarily those of the NIHR or the UK Department of Health and Social Care. This work was supported by funding from the Brain Tumour Bank and Research Fund, North Bristol NHS Trust Charitable Funds (Registered Charity Number: 1055900), and University of Bristol Campaigns and Alumni funding. This work was supported by CRUK [grant number C18281/A19169], as part of the Integrative Cancer Epidemiology Programme. MTR, MMCE, and YBS are supported by the NIHR Applied Research Collaboration West (NIHR ARC West). The views expressed in this article are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Independent Scientific Advisory Committee (ISAC) for the UK Medicines and Healthcare Products Regulatory Agency (ISAC protocol number: 18_149R)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* Joint senior authors
Funding The MRC/University of Bristol Integrative Epidemiology Unit (IEU) is supported by the MRC and the University of Bristol (MC_UU_12013/1, MC_UU_12013/2). JWR is supported by a joint studentship from NHS North Bristol Trust and Bristol Tumour Bank (SOCS/SJ1447). RMM is supported by a Cancer Research UK Programme Grant, the Integrative Cancer Epidemiology Programme (C18281/A19169). JWR and RMM are members of the MRC IEU which is supported by the Medical Research Council and the University of Bristol (MC_UU_12013/1-9). RMM is supported by the National Institute for Health Research (NIHR) Bristol Biomedical Research Centre which is funded by the National Institute for Health Research and is a partnership between University Hospitals Bristol NHS Trust and the University of Bristol. The views expressed in this publication are those of the author(s) and not necessarily those of the NIHR or the UK Department of Health and Social Care. This work was supported by funding from the Brain Tumour Bank and Research Fund, North Bristol NHS Trust Charitable Funds (Registered Charity Number: 1055900), and University of Bristol Campaigns and Alumni funding. This work was supported by CRUK [grant number C18281/A19169], as part of the Integrative Cancer Epidemiology Programme. MTR, MMCE, and YBS are supported by the NIHR Applied Research Collaboration West (NIHR ARC West). The views expressed in this article are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.
Conflict of Interest The authors have no competing interests to declare.
Authorship Performed data management and statistical analyses: JWR, MO. Writing of the initial versions of the manuscript: JWR, RMM & YBS. Extraction of CPRD data: MMCE, MTR. Conceptualisation of analysis plan: MO, MTR, RMM, KMK, YBS. All authors read, reviewed and provided feedback for final manuscript.
Data Availability
Data were obtained from Clinical Practice Research Datalink under ISAC protocol number 18_149R. Researchers who wish to obtain the same data can do so under a license agreement, including the payment of appropriate license fees, between that third party and Clinical Practice Research Datalink.
